What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
Transplantation, Internal medicine, Surgery, Gastroenterology and Fludarabine are his primary areas of study.
His Transplantation research includes themes of Preparative Regimen, Immunology and Survival rate.
His Internal medicine study frequently draws connections between adjacent fields such as Oncology.
The Surgery study which covers Rituximab that intersects with Follicular lymphoma.
Issa F. Khouri has included themes like Absolute neutrophil count, Refractory, Tacrolimus, Cumulative incidence and Graft-versus-host disease in his Gastroenterology study.
The concepts of his Hematopoietic stem cell transplantation study are interwoven with issues in ThioTEPA and Immunosuppression.
His most cited work include:
- Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy (1097 citations)
- Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. (896 citations)
- Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation (572 citations)
What are the main themes of his work throughout his whole career to date?
Issa F. Khouri spends much of his time researching Internal medicine, Transplantation, Surgery, Gastroenterology and Oncology.
His study in Hematopoietic stem cell transplantation, Fludarabine, Melphalan, Regimen and Rituximab falls within the category of Internal medicine.
His Transplantation research incorporates elements of Leukemia, Immunology, Cyclophosphamide and Stem cell.
His study in Bone marrow extends to Surgery with its themes.
His Gastroenterology study integrates concerns from other disciplines, such as Median follow-up, Busulfan, Tacrolimus, Cumulative incidence and Preparative Regimen.
Issa F. Khouri has researched Oncology in several fields, including Cancer, Myeloid leukemia, Lymphoblastic Leukemia and Lymphoma.
He most often published in these fields:
- Internal medicine (78.48%)
- Transplantation (62.15%)
- Surgery (45.08%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (78.48%)
- Transplantation (62.15%)
- Oncology (30.98%)
In recent papers he was focusing on the following fields of study:
Issa F. Khouri mainly focuses on Internal medicine, Transplantation, Oncology, Gastroenterology and Hematopoietic stem cell transplantation.
Many of his studies on Internal medicine apply to Surgery as well.
His Transplantation study combines topics from a wide range of disciplines, such as Hazard ratio, Cyclophosphamide, Stem cell and Rituximab.
His Oncology research integrates issues from Leukemia, Lymphoblastic Leukemia and Myeloid leukemia.
His research integrates issues of Median follow-up and Cumulative incidence in his study of Gastroenterology.
His Hematopoietic stem cell transplantation research includes elements of Overall survival, Cohort and Multiple myeloma.
Between 2015 and 2021, his most popular works were:
- Results of a 2‐arm, phase 2 clinical trial using post‐transplantation cyclophosphamide for the prevention of graft‐versus‐host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation (52 citations)
- Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia (51 citations)
- Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation (36 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
